EMA Withdrawn: Extavia (interferon beta-1b) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency has withdrawn Extavia (interferon beta-1b) for multiple sclerosis, with Novartis Europharm Limited as the marketing authorization …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Extavia (interferon beta-1b)

Snippet

Status: Withdrawn. Therapeutic area: Multiple Sclerosis. MAH: Novartis Europharm Limited. Decision date: 08/12/2022